



US009636346B2

(12) **United States Patent**  
**Kobayashi et al.**

(10) **Patent No.:** **US 9,636,346 B2**

(45) **Date of Patent:** **\*May 2, 2017**

(54) **ALPHA-OXOACYL AMINO-CAPROLACTAM  
DERIVATIVE**

(71) Applicant: **Seikagaku Corporation**, Tokyo (JP)

(72) Inventors: **Nobuo Kobayashi**, Tokyo (JP); **Tsuneo Koji**, Tokyo (JP); **Hisatomo Kunii**, Tokyo (JP); **Mizuho Ishikawa**, Tokyo (JP); **Daisuke Morita**, Tokyo (JP)

(73) Assignee: **Seikagaku Corporation**, Tokyo (JP)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/263,969**

(22) Filed: **Sep. 13, 2016**

(65) **Prior Publication Data**

US 2016/0375031 A1 Dec. 29, 2016

#### Related U.S. Application Data

(63) Continuation of application No. 14/898,242, filed as application No. PCT/JP2014/003158 on Jun. 13, 2014, now Pat. No. 9,481,707.

(30) **Foreign Application Priority Data**

Jun. 14, 2013 (JP) ..... 2013-125181

(51) **Int. Cl.**

**A61K 38/00** (2006.01)

**A61K 31/55** (2006.01)

**C07K 5/02** (2006.01)

**C07K 5/065** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/55** (2013.01); **C07K 5/0202** (2013.01); **C07K 5/06078** (2013.01); **A61K 38/00** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 38/00**  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

3,740,405 A 6/1973 Kraft  
6,117,870 A 9/2000 Hosoda et al.

#### FOREIGN PATENT DOCUMENTS

JP 49-831 B1 1/1974  
JP 1974000831 A 1/1974  
JP 2000204071 A 7/2000  
JP 2007-236327 A 9/2007  
WO 9801133 A1 1/1998  
WO 0158886 A1 8/2001  
WO 03075836 A2 9/2003

#### OTHER PUBLICATIONS

International Search Report for corresponding International Application Ser. No. PCT/JP2014/003158, filed Jun. 13, 2014, 2 pages.  
Inaoka T et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. *Biochem Biophys Res Commun.* Jan. 5, 1995;206(1):89-96.  
Drake FH et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. *J Biol Chem.* May 24, 1996;271(21):12511-6.  
Gelb BD et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. *Science.* Aug. 30, 1996;273(5279):1236-8.  
Brömme D et al. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in *Spodoptera frugiperda* and characterization of the enzyme. *J Biol Chem.* Jan. 26, 1996;271(4):2126-32.  
Aibe K et al., Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. *Biol Pharm Bull.* Aug. 1996;19(8):1026-31.  
McGrath ME et al., Crystal structure of human cathepsin K complexed with a potent inhibitor. *Nat Struct Biol.* Feb. 1997;4(2):105-9.  
Palmer JT et al., Vinyl sulfones as mechanism-based cysteine protease inhibitors. *J Med Chem.* Aug. 18, 1995;38(17):3193-6.  
Brömme D et al., Peptide methyl ketones as reversible inhibitors of cysteine proteinases. *J Enzyme Inhib.*  
Tsujiinaka T et al., Synthesis of a new cell penetrating calpain inhibitor (calpeptin). *Biochem Biophys Res Commun.* Jun. 30, 1988;153(3):1201-8.  
Hashida S et al., Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. *J Biochem.* Dec. 1980;88(6):1805-11.  
Zhao B. et al., Crystal structure of human osteoclast cathepsin K complex with E-64. *Nat Struct Biol.* Feb. 1997;4(2):109-11.  
Thompson SK et al., Design of potent and selective human cathepsin K inhibitors that span the active site. *Proc Natl Acad Sci U S A.* Dec. 23, 1997;94(26):14249-54.

(Continued)


*Primary Examiner* — Bruck Kifle

(74) *Attorney, Agent, or Firm* — Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.; Peter F. Corless; Christopher R. Cowles

(57) **ABSTRACT**

The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in combination with another drug. The present invention relates to: an  $\alpha$ -oxoacyl amino-caprolactam derivative that is represented by formula (I)

(I)



(in the formula, X is —O— or —N(R<sup>1</sup>)— and R<sup>1</sup> represents an alkoxy carbonyl group having 1-10 carbon atoms); and a bone resorption inhibitor containing the  $\alpha$ -oxoacyl amino-caprolactam derivative.

**4 Claims, No Drawings**